180
Participants
Start Date
November 7, 2016
Primary Completion Date
August 3, 2020
Study Completion Date
March 14, 2025
Gemcitabine
Nab-paclitaxel
Durvalumab
Tremelimumab
Tom Baker Cancer Centre, Calgary
BCCA - Vancouver Cancer Centre, Vancouver
CancerCare Manitoba, Winnipeg
The Moncton Hospital, Moncton
The Vitalite Health Network - Dr. Leon Richard, Moncton
Dr. H. Bliss Murphy Cancer Centre, St. John's
QEII Health Sciences Centre, Halifax
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Kingston Health Sciences Centre, Kingston
Grand River Regional Cancer Centre, Kitchener
London Regional Cancer Program, London
Ottawa Hospital Research Institute, Ottawa
Algoma District Cancer Program, Sault Ste. Marie
Niagara Health System, St. Catharines
Odette Cancer Centre, Toronto
University Health Network, Toronto
St. Joseph's Health Centre, Toronto
Hopital de la Cite-de-la-Sante, Laval
L'Hotel-Dieu de Levis, Lévis
CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal
The Jewish General Hospital, Montreal
The Research Institute of the McGill University, Montreal
Centre Integre Universitaire De Sante Et De Services, Montreal
CHUQ-Pavillon Hotel-Dieu de Quebec, Québec
Centre hospitalier universitaire de Sherbrooke, Sherbrooke
Allan Blair Cancer Centre, Regina
Saskatoon Cancer Centre, Saskatoon
Collaborators (1)
AstraZeneca
INDUSTRY
Canadian Cancer Trials Group
NETWORK